Source link : https://www.newshealth.biz/health-news/leqembi-okayed-for-subset-of-early-alzheimers-patients/
The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for Leqembi (lecanemab) to treat mild cognitive impairment and early Alzheimer’s disease, following a re-examination of the clinical data. The recommendation is only for patients who have one or no copies of the apolipoprotein E4 (APOE4) gene […]
Author : News Health
Publish date : 2024-11-15 15:58:23
Copyright for syndicated content belongs to the linked Source.
Categories